Bicycle Therapeutics Reports Interim BT8009 Phase I Clinical Trial Results
Bicycle Therapeutics Limited plc (NASDAQ: BCYC) reported interim Phase I results from the Phase I/II trial of BT8009, a second generation BTC that targets Nectin-4. Results were presented on Sunday April 10th, at the 2022 American Association for Cancer Research Annual Meeting In New Orleans, LA. “Since our initial BT8009 Phase I/II trial interim results …
Bicycle Therapeutics Reports Interim BT8009 Phase I Clinical Trial Results Read More »